Sera Prognostics Inc (SERA)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $79.94M
Last updated: Nov 17, 2026 at 3:04 AM ET
Sera Prognostics Inc (SERA) Earnings: Report Dates and Results
Sera Prognostics (SERA) is expected to report earnings on Mar 16, 2027. In the quarter ended Sep 30, 2026, Sera Prognostics reported EPS of -$0.16, below the -$0.14 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
SERA has an expected report date of Mar 16, 2027.
SERA Earnings Call
The latest SERA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, SERA beat 13, missed 8 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $42000, up 162.5% from $16000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.16 | -$0.14 | -$0.18 - -$0.10 | -14.29% | Miss | N/A | 4 | 2 up, 0 down | Nov 4, 2026 | $42000 |
| Jun 30, 2026 | -$0.18 | -$0.14 | -$0.19 - -$0.13 | -28.57% | Miss | N/A | 3 | 0 up, 0 down | Aug 12, 2026 | $30000 |
| Mar 31, 2026 | -$0.17 | -$0.17 | -$0.18 - -$0.16 | 0.00% | In line | N/A | 3 | 1 up, 0 down | May 6, 2026 | $14000 |
| Dec 31, 2025 | -$0.16 | -$0.19 | -$0.20 - -$0.17 | +13.70% | Beat | N/A | 3 | 1 up, 0 down | Mar 18, 2026 | $10000 |
| Sep 30, 2025 | -$0.16 | -$0.21 | -$0.21 - -$0.21 | +23.81% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2025 | $16000 |
| Jun 30, 2025 | -$0.16 | -$0.24 | -$0.24 - -$0.24 | +33.33% | Beat | N/A | 1 | 0 up, 1 down | Aug 6, 2025 | $17000 |
| Mar 31, 2025 | -$0.20 | -$0.21 | -$0.21 - -$0.21 | +4.76% | Beat | N/A | 1 | 1 up, 0 down | May 7, 2025 | $38000 |
| Dec 31, 2024 | -$0.25 | -$0.23 | -$0.25 - -$0.23 | -8.70% | Miss | N/A | 2 | 1 up, 0 down | Mar 19, 2025 | $24000 |
| Sep 30, 2024 | -$0.24 | -$0.22 | -$0.22 - -$0.22 | -9.09% | Miss | N/A | 2 | 0 up, 0 down | Nov 6, 2024 | $29000 |
| Jun 30, 2024 | -$0.25 | -$0.26 | -$0.30 - -$0.23 | +3.85% | Beat | N/A | 2 | 0 up, 0 down | Aug 7, 2024 | $24000 |
| Mar 31, 2024 | -$0.25 | -$0.27 | -$0.31 - -$0.23 | +7.41% | Beat | N/A | 2 | 0 up, 0 down | May 8, 2024 | N/A |
| Dec 31, 2023 | -$0.25 | -$0.26 | -$0.27 - -$0.25 | +3.85% | Beat | N/A | 2 | 0 up, 0 down | Mar 20, 2024 | $41000 |
| Sep 30, 2023 | -$0.23 | -$0.35 | -$0.36 - -$0.30 | +34.29% | Beat | N/A | 3 | 0 up, 0 down | Nov 8, 2023 | $42000 |
| Jun 30, 2023 | -$0.34 | -$0.36 | -$0.39 - -$0.34 | +5.56% | Beat | N/A | 3 | 1 up, 0 down | Aug 9, 2023 | $123000 |
| Mar 31, 2023 | -$0.34 | -$0.38 | -$0.41 - -$0.35 | +10.53% | Beat | N/A | 3 | 0 up, 0 down | May 10, 2023 | $100000 |
| Dec 31, 2022 | -$0.31 | -$0.37 | -$0.44 - -$0.29 | +16.22% | Beat | N/A | 4 | 0 up, 0 down | Mar 22, 2023 | $65000 |
| Sep 30, 2022 | -$0.35 | -$0.62 | -$1.10 - -$0.34 | +43.55% | Beat | N/A | 4 | 0 up, 0 down | Nov 9, 2022 | $87000 |
| Jun 30, 2022 | -$0.37 | -$0.41 | -$0.46 - -$0.37 | +9.76% | Beat | N/A | 4 | 0 up, 0 down | Aug 10, 2022 | $78000 |
| Mar 31, 2022 | -$0.40 | -$0.37 | -$0.41 - -$0.33 | -8.11% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2022 | $38000 |
| Dec 31, 2021 | -$0.41 | -$0.29 | -$0.40 - -$0.18 | -41.38% | Miss | N/A | 4 | 0 up, 0 down | Mar 29, 2022 | $26000 |
| Sep 30, 2021 | -$0.39 | -$0.25 | -$0.29 - -$0.22 | -56.00% | Miss | N/A | 3 | N/A | Nov 9, 2021 | $23000 |
| Jun 30, 2021 | -$3.17 | -$1.26 | N/A | -151.59% | Miss | N/A | N/A | N/A | Jul 16, 2021 | $20000 |
| Mar 31, 2021 | -$0.17 | -$0.17 | N/A | 0.00% | In line | N/A | N/A | N/A | Jun 2, 2021 | $13000 |
| Dec 31, 2020 | -$1.71 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $6000 |
| Dec 31, 2019 | -$1.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.68, after -$0.99 the year before. It was -$1.48 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.68 | N/A |
| Dec 31, 2024 | -$0.99 | N/A |
| Dec 31, 2023 | -$1.16 | N/A |
| Dec 31, 2022 | -$1.43 | N/A |
| Dec 31, 2021 | -$4.14 | N/A |
| Dec 31, 2020 | -$1.71 | N/A |
| Dec 31, 2019 | -$1.48 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,778 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,826 | 8 | |
| 2026Q1 | Mar 31, 2026 | 3,569 | 6 | |
| 2025Q4 | Dec 31, 2025 | 4,350 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,356 | 6 | |
| 2025Q2 | Jun 30, 2025 | 3,414 | 6 | |
| 2025Q1 | Mar 31, 2025 | 4,229 | 6 | |
| 2024Q4 | Dec 31, 2024 | 4,934 | 6 |
2026Q3 Earnings Call
Opening remarks
Jennifer Zibuda Head of Investor Relations Thank you, operator. Welcome to Sera Prognostics Third Quarter 2026 Earnings Conference Call. Earlier today, Sera reported financial results for the quarter, which ended September 30, 2026. Joining me on today's call are Zhenya Lindgardt, President and Chief Executive Officer; Lee Anderson, Chief Commercial Officer; Tiffany Inglis, Chief Medical Officer; and Scott Gleason, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. A copy of today's earnings release can be found on the Investors section of our website at sera.com, and a replay of this webcast will also be available. We have also posted an accompanying slide deck presentation pertaining to today's earnings call on the Events section of our Investor Relations website. Before we begin, please note that today's discussion will include projections or forward-looking statements about events and circumstances that have not yet occurred, including regarding our business, future financial results and performance, and market opportunities. These statements are based on our current expectations and are subject to risk factors and uncertainties that could cause actual results to differ materially and adversely from these expectations and forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q, and 8-K, for important information regarding these risk factors. With that, I will turn the call over to Zhenya.
Evguenia Lindgardt President and Chief Executive Officer Good afternoon, everyone, and thank you for joining us today. At Sera, we believe we're building something truly unique in health care. We have developed one of the most highly validated advanced lab tests in history, addressing one of the most important and underserved challenges in medicine: preterm birth. The PreTRM test has demonstrated the ability to identify high-risk pregnancies early and drive meaningful improvements in outcomes for mothers and babies. We're no longer simply an evidence-generation story. We're actively transitioning into the commercialization phase of our journey, with the goal of establishing PreTRM as a foundational component of prenatal care. The opportunity remains largely untapped, with no effective standard for broad population screening of preterm birth risk. As a result, we believe there is the potential to create a new category in prenatal care and address one of the largest unmet needs in health care while driving substantial long-term value for shareholders. The third quarter represented a significant step forward in that journey. Following publication of the landmark PRIME study and the addition of highly experienced commercial leaders to our management team, we saw strong momentum in the third quarter. Compared to the first quarter of this year, the number of physicians ordering PreTRM nearly tripled, while test volume increased approximately fivefold.
Frequently Asked Questions About SERA
When is Sera Prognostics's next earnings date?
Sera Prognostics's next earnings report is expected for Mar 16, 2027.
Did SERA beat earnings estimates last quarter?
No. Sera Prognostics reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.14 estimate by 14.29%.
What EPS do analysts expect from SERA next quarter?
The consensus EPS estimate for Sera Prognostics for the quarter ending Dec 31, 2026 is -$0.16 from 6 analysts, with estimates from -$0.19 to -$0.15.
How often does SERA beat earnings estimates?
Sera Prognostics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +3.01%.
SERA pages: Overview, Earnings, Forecast, Financials, Competitors